Table 1.

Pivotal randomized placebo-controlled trials of erenumab in migraine.

Trial patients	Treatment modalities	Endpoints	Outcome (erenumab vs. placebo)
Episodic migraine
Dodick et al. (ARISE) (13) 577 adults 8 monthly migraine days on average	70 mg subcut monthly vs. placebo	Primary: change in monthly migraine days (MMD) during DB phase weeks 9–12 vs. baseline	−2.9 vs. −1.8 MMD Mean difference (95% CI): −1.0 (−1.6/−0.5)
Duration of double-blind (DB) phase: 12 weeks		Secondary : ≥50% responder rate	39.7% vs. 29.5% Odds ratio (95% CI) 1.59 (1.12/2.27)
Goadsby et al. (STRIVE) (12) 955 adults 8 monthly migraine days on average Duration of DB phase: 24 weeks	70 mg subcut monthly vs. placebo 140 mg subcut monthly vs. placebo	Primary: change in monthly migraine days (MMD) during DB phase weeks 13–24 vs. baseline Secondary: ≥50% responder rate Primary: change in monthly migraine days (MMD) during DB phase weeks 13–24 vs. baseline Secondary: ≥50% responder rate	−3.2 vs. −1.8 MMD Mean difference (95% CI): −1.4 (−1.9/−0.9) 43.3% vs. 26.6% Odds ratio (95% CI) 2.13 (1.52/2.98) −3.7 vs. −1.8 MMD Mean difference (95% CI): −1.9 (−2.3/−1.4) 50% vs. 26.6% Odds ratio (95% CI) 2.81 (2.01/3.94)
Chronic migraine
Tepper et al. (14) 667 adults 18 monthly migraine days on average Duration of DB phase: 12 weeks	70 mg subcut monthly vs. placebo 140 mg subcut monthly vs. placebo	Primary: change in monthly migraine days (MMD) during DB phase weeks 9–12 vs. baseline Secondary: ≥50% responder rate Primary: change in monthly migraine days (MMD) during DB phase weeks 9–12 vs. baseline Secondary: ≥50% responder rate	−6.6 vs. −4.2 MMD Mean difference (95% CI): −2.5 (−3.5/−1.4) 40% vs. 23% Odds ratio (95% CI) 2.2 (1.5/3.3) −6.6 vs. −4.2 MMD Mean difference (95% CI): −2.5 (−3.5/−1.4) 41% vs. 23% Odds ratio (95% CI) 2.3 (1.6/3.5)
Episodic or chronic migraine with preventive treatment failures
Reuter et al. (15) 226 adults 9 monthly migraine days on average Duration of DB phase: 12 weeks	140 mg subcut monthly vs. placebo	Primary: ≥50% responder rate during DB phase weeks 9–12 vs. baseline Secondary: change in monthly migraine days (MMD) during DB phase weeks 9–12 vs. baseline	30% vs. 14% Odds ratio (95% CI) 2.7 (−1.4/−5.2) −1.8 vs. −0.2 MMD Mean difference (95% CI): −1.6 (−2.7/−0.5)